The FDA's July 2026 compounding advisory committee backed six of seven peptides against its own scientists' advice. What that vote means, what it does not mean, and what the FDA review documents actually found.
On 23 and 24 July 2026, the United States Food and Drug Administration convened its Pharmacy Compounding Advisory Committee (PCAC) to review seven peptides that have circulated in the research and wellness markets for years. The coverage that followed was almost uniformly wrong in the same direction: headlines announced that the FDA had "cleared" or "approved" BPC-157 and TB-500.
It did not. This article works through what the FDA's own review documents say, what the committee actually voted on, and where the line sits between "eligible to be compounded" and "shown to work."
How to read this article. Every factual claim about the meeting is drawn from the FDA's published briefing packages, linked in full at the end. Vote tallies are as reported in meeting coverage; the FDA has not published final minutes.
The PCAC is a standing federal advisory committee. It advises the FDA's Center for Drug Evaluation and Research on which bulk drug substances pharmacies may lawfully use when compounding medicines. Over two days at the FDA's White Oak campus it worked through seven peptides, voting separately on the free base and the acetate salt of each — fourteen votes in total.
Two details from the FDA briefing package are easy to miss and worth stating plainly.
First, both nominators had already withdrawn their nominations. LDT Health Solutions, Inc. (on behalf of the International Peptide Society) and Wells Pharmacy Network pulled their submissions, and the FDA elected to present the substances to the committee regardless. Every substance carries that footnote.
Second, the FDA's own review team proposed rejecting all fourteen. The briefing document is unambiguous, repeating for each one that the agency "is proposing that [the substance] NOT be included on the 503A Bulks List."
The committee overruled its own agency scientists on six of the seven. Reported tallies were roughly 8–6 for BPC-157, KPV and TB-500, 7–5 for MOTS-c, 8–5 for Semax and 7–4 for Epitalon. Emideltide failed 6–7. Every margin was narrow.
A 15-amino-acid sequence first described in 1993 as a fragment of a protein isolated from gastric juice. It was nominated for ulcerative colitis, Crohn's disease, coeliac disease and tendonitis across oral, rectal, transdermal, subcutaneous and nasal routes. The FDA evaluated it for ulcerative colitis.
The human evidence is thinner than its reputation suggests: a placebo-controlled phase 1 study in 32 healthy subjects, and a multicentre ulcerative colitis trial published only as a conference abstract, both using a rectal enema for at most two weeks. In that trial the mean disease-activity change was −3.2 with BPC-157 against −1.6 with placebo — a between-group estimate whose confidence interval crossed zero.
Evidence gaps: no human studies at all by the oral, subcutaneous, nasal or transdermal routes; no human pharmacokinetic data; no identified molecular target and no established dose–response even in rodents; unassessed aggregation and immunogenicity risk.
A seven-amino-acid acetylated peptide (Ac-LKKTETQ) corresponding to residues 17–23 of the 43-amino-acid protein thymosin β4. The FDA document corrects a very common error head-on: TB-500 and thymosin β4 are not the same substance, despite websites using the terms interchangeably. It was nominated for wound healing by intramuscular and subcutaneous injection.
Human evidence: none. The FDA found no medical literature in which TB-500 was administered to patients for any condition whatsoever.
Evidence gaps: no in-vivo nonclinical wound-healing study was identified; one in-vitro scratch-wound experiment found no effect at 50 µg/mL; no toxicity studies exist; injectable routes carry particular immunogenicity concern.
The tripeptide lysine–proline–valine, the C-terminal fragment α-MSH(11–13) of α-melanocyte-stimulating hormone. Nominated for wound healing and inflammatory skin conditions such as psoriasis and eczema, in a cream or gel.
Human evidence: none, by any route.
Evidence gaps: no certificate of analysis was supplied with the nomination; no published impurity, aggregate or microbiological data; low water solubility (0.7 mg/mL) with no formulation details, so the FDA could not assess how a finished cream would even perform.
A 16-amino-acid mitochondria-derived peptide encoded within an open reading frame of the 12S rRNA gene (MT-RNR1), first described in 2015. Nominated for injection; the FDA evaluated obesity and osteoporosis.
Human evidence: none identified.
Evidence gaps: the biology rests entirely on in-vitro and rodent work, with no dose–response characterisation and unknown molecular targets — the FDA noted it cannot predict which organs would be affected. MOTS-c is also a prohibited substance in sport under the World Anti-Doping Agency's hormone and metabolic modulators class.
A heptapeptide, an ACTH(4–7) analogue extended with Pro-Gly-Pro, and a registered drug in Russia sold as 0.1% and 1% nasal drops. Nominated for subcutaneous and intranasal use; the FDA evaluated cerebral ischaemia, migraine and trigeminal neuralgia.
Human evidence amounts to two references with insufficient methodological detail which, in the FDA's reading, demonstrated a lack of effectiveness and were limited by small sample size.
Evidence gaps: no human pharmacokinetic data by any route; no safety data at all for the proposed subcutaneous route; a possible antithrombotic effect raising bleeding questions that compounded labelling would not warn about; and, in mice, potentiation of amphetamine-induced striatal dopamine release — an abuse-potential signal that has never been followed up.
The tetrapeptide Ala-Glu-Asp-Gly, developed from work on pineal gland extracts. Nominated for subcutaneous injection; the FDA evaluated insomnia.
Human evidence is limited to reports of changes in melatonin or melatonin-metabolite levels. There are no studies in patients with insomnia, and none by the subcutaneous route.
Evidence gaps: the mechanism by which it affects melatonin is unknown; no sleep endpoints, behavioural or EEG, were studied even in animals. And because epitalon activates telomerase and lengthens telomeres, the FDA raised a carcinogenicity concern — the opposite of how the compound is usually marketed — which the available mouse studies (fixed dose, females only, short exposure) cannot resolve.
A nonapeptide, better known as delta sleep-inducing peptide, traced to work published in the 1960s and 1970s. Nominated for subcutaneous use in chronic insomnia, narcolepsy and opioid withdrawal.
It has the longest human track record of the seven — studied in people since at least 1981 — but almost entirely by the intravenous route, in small, largely uncontrolled or unblinded studies reaching inconsistent conclusions. Reported side effects in withdrawal patients included transient headache, nausea, vertigo, and progressive hypotension after a second intravenous dose.
Evidence gaps: no safety or efficacy data for the proposed subcutaneous route; DSIP stimulates endorphin release, raising an addiction question never studied nonclinically; it appears in no clinical practice guideline. It was the committee's only rejection.
| Peptide | What it is | Use the FDA evaluated | Human evidence found | FDA proposal | Committee vote |
|---|---|---|---|---|---|
| BPC-157 | 15-aa gastric protein fragment | Ulcerative colitis | Phase 1 (n=32) plus one abstract-only trial, rectal, 2 weeks | Do not add | 8–6 in favour |
| TB-500 | 7-aa fragment of thymosin β4 | Wound healing | None | Do not add | 8–6 in favour |
| KPV | Tripeptide, α-MSH(11–13) | Wound healing, inflammatory skin | None | Do not add | 8–6 in favour |
| MOTS-c | 16-aa mitochondria-derived peptide | Obesity, osteoporosis | None | Do not add | 7–5 in favour |
| Semax | Heptapeptide, ACTH(4–7) analogue | Cerebral ischaemia, migraine, trigeminal neuralgia | Two poorly detailed studies; no PK | Do not add | 8–5 in favour |
| Epitalon | Tetrapeptide AEDG | Insomnia | Melatonin-level studies only | Do not add | 7–4 in favour |
| Emideltide (DSIP) | Nonapeptide | Insomnia, narcolepsy, opioid withdrawal | Small IV studies since 1981; inconclusive | Do not add | 6–7 against |
Note: votes were taken separately on free base and acetate forms. Tallies above are as reported in meeting coverage.
Section 503A of the US Federal Food, Drug, and Cosmetic Act exempts drugs compounded by a licensed pharmacist or physician from three otherwise-mandatory requirements: premarket approval, labelling with adequate directions for use, and current good manufacturing practice.
To qualify, the bulk substance used must be one of three things: compliant with a USP or NF monograph; a component of an already-approved drug; or on the 503A Bulks List. None of these seven peptides meets the first two conditions, which is why the list is the only available door.
The FDA's 2019 final rule sets four criteria, applied as a balancing test: physical and chemical characterisation; safety issues raised by use in compounding; available evidence of effectiveness or lack of it; and historical use in compounding. Critically, the list makes a substance eligible as a starting material. It says nothing about any particular finished product.
It means a panel of outside experts, having heard the FDA's review and public testimony, has given the agency non-binding advice. The FDA usually follows such advice, but is under no obligation to — and in this case the recommendation ran directly against its own reviewers' conclusions.
Approval requires a sponsor to submit adequate and well-controlled clinical trials, a fully specified manufacturing process, and proposed labelling — all reviewed before marketing and monitored afterwards.
A bulks listing involves none of that. It is a judgement that a substance is an acceptable starting material for a patient-specific preparation, in cases where an approved product cannot meet a particular patient's need. There is no efficacy standard to clear, no approved labelling, and no premarket quality review of the resulting product. The two decisions are not on the same scale; they are not even measuring the same thing.
This is where most commentary collapses, so it is worth separating cleanly.
Is the raw substance what it claims to be? The FDA concluded that not one of the seven is well characterised. Naming conventions do not follow USAN, INN or IUPAC standards, and the certificates of analysis lacked tests for peptide-related impurities, aggregates, microbial bioburden and bacterial endotoxin. That is a documentation and analytics problem, and it is solvable — see our guide to reading a CoA for what a complete one actually contains.
Can it be made into a sound finished product? A separate question. The FDA raised container-closure gaps for the proposed nasal sprays, solubility problems (DSIP could not obviously be formulated at the proposed injectable concentration at all), and aggregation-driven immunogenicity risk that is highest for injected routes.
Does it work? Separate again, and unaffected by either of the above. A compound can be 99.5% pure, correctly identified and endotoxin-free — and still do nothing. Conversely, a molecule with genuine biology can be delivered in an unsafe preparation. Purity is not evidence, and evidence is not purity. A certificate of analysis tells you what is in the vial. It does not tell you what the contents do.
The FDA now finalises its reviews and weighs the committee's advice alongside public comments — reportedly around 2,659 of them.
If the agency decides to add any substance, it must go through notice-and-comment rulemaking: a proposed rule in the Federal Register, a comment period, then a final rule. That process has historically taken well over a year, and only around ten substances have ever completed it.
The FDA may also simply decline; it has already put its scientific position on the record for all seven. Separately, the agency removed these peptides from Category 2 — the interim list of substances that may present significant safety risks — in April 2026. That removed a warning designation, not a prohibition, and it did not authorise compounding. A further PCAC meeting is expected before February 2027 covering GHK-Cu, melanotan II, cathelicidin LL-37, dihexa acetate and PEG-MGF.
No. This is a United States regulatory process operating under US law. The 503A framework has no Australian equivalent and no effect here; peptide classification in Australia is a matter for the TGA and the Poisons Standard, neither of which is touched by a PCAC vote.
What does travel across borders is the evidence assessment. The FDA reviewers read the same published literature available to anyone, and their conclusions — no human data for four of these compounds, incomplete characterisation for all seven — are statements about the global scientific record, not about US law. Those findings are as true in Melbourne as in Maryland.
Did the FDA approve BPC-157 or TB-500?
No. Neither is FDA-approved for any use, and an advisory committee vote is not an approval.
Can US pharmacies compound these peptides now?
No. The substances are not on the 503A Bulks List, so the statutory condition is not met. Only a final rule would change that.
Why did the FDA review substances whose nominations had been withdrawn?
The briefing document states that both nominators withdrew and that the FDA elected to proceed with the presentations regardless.
Does "no evidence of harm" mean these are safe?
No. For four of the seven the FDA found no human exposure data at all. That means the safety profile is unknown, not clean. Those are different claims.
Is TB-500 the same as thymosin β4?
No. TB-500 is a seven-amino-acid fragment; thymosin β4 is a 43-amino-acid protein. The FDA explicitly corrects this conflation, which matters because much of the clinical literature cited for TB-500 is actually about thymosin β4.
Are these compounds allowed in competitive sport?
MOTS-c is listed as prohibited under WADA's hormone and metabolic modulators class, and several others fall within prohibited categories. Nothing about this vote changes that.
For a closer look at the underlying preclinical literature on two of these compounds, see our companion article on what the BPC-157 and TB-500 evidence actually shows.
Disclaimer: This article summarises publicly available regulatory documents and published research literature for educational purposes. It is not medical, legal or regulatory advice, and it contains no dosing, route or administration guidance. None of the compounds discussed has been shown by adequate and well-controlled clinical trials to be safe or effective for the uses described. All products supplied are strictly for in-vitro laboratory and research use, not for human consumption.
Learn the correct technique for reconstituting lyophilised research peptides using bacteriostatic water for accurate, contamination-free preparations.
Research GuidesProper storage is critical to maintaining peptide integrity. Learn the correct temperature requirements and handling practices for lyophilised and reconstituted peptides.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides